BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, announced today that it has promoted Andrea Matthews to Chief Business Officer. Ms. Matthews brings 20 years of business experience to the role and has been with the company for close to nine years, most recently as Senior Vice President, Corporate Affairs.
“Andrea has made important contributions to significant inflection points over her years at the company,” said Jill C. Milne, Chief Executive Officer at Astria. “We are thrilled that her expanded role will enable the company to prioritize our strategic growth and help us meet our goals of building our pipeline and continuing the development of our lead program, STAR-0215.”
“Our patients-first mission is a critical part of our vision for Astria now and in the future,” said Ms. Matthews. “I am looking forward to building upon the work we have done with STAR-0215 with a team devoted to bringing life-changing therapies to patients and families.”
Ms. Matthews will be responsible for leading the company’s Corporate Strategy, Business Development, Investor Relations, Corporate Communications, and Patient Advocacy functions. Most recently, she served as Senior Vice President, Corporate Affairs at Astria, since October 2020. Previously, she served as Vice President, Corporate Affairs since 2017, Executive Director, Corporate Affairs since 2015, and Senior Director, Operations and Corporate Development since 2014. Prior to joining Astria, Ms. Matthews served as Vice President, Operations and Alliance Management/Commercial Operations at Selventa (formerly Genstruct) from 2010 and Director, Alliance Management from 2009. From 2003 to 2009, Ms. Matthews held a series of roles with increasing responsibility at Genstruct. Ms. Matthews holds an M.B.A. from the Massachusetts Institute of Technology Sloan School of Management and a B.A. in Biochemistry and Molecular Biology from Boston University.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.
